These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1185 related articles for article (PubMed ID: 23209033)

  • 21. Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation status.
    Ohno M; Narita Y; Miyakita Y; Okita Y; Matsushita Y; Yoshida A; Fukushima S; Ichimura K; Kayama T; Shibui S
    Brain Tumor Pathol; 2012 Oct; 29(4):183-91. PubMed ID: 22790483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary and secondary glioblastomas: from concept to clinical diagnosis.
    Kleihues P; Ohgaki H
    Neuro Oncol; 1999 Jan; 1(1):44-51. PubMed ID: 11550301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IDH1 mutation can be present in diffuse astrocytomas and giant cell glioblastomas of young children under 10 years of age.
    Ferris SP; Goode B; Joseph NM; Kline CN; Samuel D; Gupta N; Bollen A; Perry A; Mueller S; Solomon DA
    Acta Neuropathol; 2016 Jul; 132(1):153-5. PubMed ID: 27161253
    [No Abstract]   [Full Text] [Related]  

  • 24. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathologic diversity of glioneuronal tumor with neuropil-like islands: a histological and immunohistochemical study with a special reference to isocitrate dehydrogenase 1 (IDH1) in 5 cases.
    Ishizawa K; Hirose T; Sugiyama K; Kageji T; Nobusawa S; Homma T; Komori T; Sasaki A
    Clin Neuropathol; 2012; 31(2):67-76. PubMed ID: 22385787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and secondary glioblastomas.
    Tohma Y; Gratas C; Van Meir EG; Desbaillets I; Tenan M; Tachibana O; Kleihues P; Ohgaki H
    J Neuropathol Exp Neurol; 1998 Mar; 57(3):239-45. PubMed ID: 9600216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes.
    Seiz M; Tuettenberg J; Meyer J; Essig M; Schmieder K; Mawrin C; von Deimling A; Hartmann C
    Acta Neuropathol; 2010 Aug; 120(2):261-7. PubMed ID: 20514489
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic alterations and signaling pathways in the evolution of gliomas.
    Ohgaki H; Kleihues P
    Cancer Sci; 2009 Dec; 100(12):2235-41. PubMed ID: 19737147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing.
    Takano S; Tian W; Matsuda M; Yamamoto T; Ishikawa E; Kaneko MK; Yamazaki K; Kato Y; Matsumura A
    Brain Tumor Pathol; 2011 Apr; 28(2):115-23. PubMed ID: 21344322
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular pathogenesis of pediatric astrocytic tumors.
    Nakamura M; Shimada K; Ishida E; Higuchi T; Nakase H; Sakaki T; Konishi N
    Neuro Oncol; 2007 Apr; 9(2):113-23. PubMed ID: 17327574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A case of an epithelioid glioblastoma with the BRAF V600E mutation colocalized with BRAF intact low-grade diffuse astrocytoma.
    Kuroda J; Nobusawa S; Nakamura H; Yokoo H; Ueda R; Makino K; Yano S; Kuratsu J
    Neuropathology; 2016 Apr; 36(2):181-6. PubMed ID: 26375727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Caveolin-1 expression is variably displayed in astroglial-derived tumors and absent in oligodendrogliomas: concrete premises for a new reliable diagnostic marker in gliomas.
    Cassoni P; Senetta R; Castellano I; Ortolan E; Bosco M; Magnani I; Ducati A
    Am J Surg Pathol; 2007 May; 31(5):760-9. PubMed ID: 17460461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Small cell astrocytoma: an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma.
    Perry A; Aldape KD; George DH; Burger PC
    Cancer; 2004 Nov; 101(10):2318-26. PubMed ID: 15470710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oligodendroglial tumors with marked desmoplasia: clinicopathologic and molecular features of 7 cases.
    Jentoft M; Giannini C; Rossi S; Mota R; Jenkins RB; Rodriguez FJ
    Am J Surg Pathol; 2011 Jun; 35(6):845-52. PubMed ID: 21552114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.
    Ueki K; Nishikawa R; Nakazato Y; Hirose T; Hirato J; Funada N; Fujimaki T; Hojo S; Kubo O; Ide T; Usui M; Ochiai C; Ito S; Takahashi H; Mukasa A; Asai A; Kirino T
    Clin Cancer Res; 2002 Jan; 8(1):196-201. PubMed ID: 11801559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss.
    Arita H; Narita Y; Fukushima S; Tateishi K; Matsushita Y; Yoshida A; Miyakita Y; Ohno M; Collins VP; Kawahara N; Shibui S; Ichimura K
    Acta Neuropathol; 2013 Aug; 126(2):267-76. PubMed ID: 23764841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
    Hartmann C; Meyer J; Balss J; Capper D; Mueller W; Christians A; Felsberg J; Wolter M; Mawrin C; Wick W; Weller M; Herold-Mende C; Unterberg A; Jeuken JW; Wesseling P; Reifenberger G; von Deimling A
    Acta Neuropathol; 2009 Oct; 118(4):469-74. PubMed ID: 19554337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequent HRK inactivation associated with low apoptotic index in secondary glioblastomas.
    Nakamura M; Ishida E; Shimada K; Nakase H; Sakaki T; Konishi N
    Acta Neuropathol; 2005 Oct; 110(4):402-10. PubMed ID: 16155764
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular subtypes of glioma identified by genome-wide methylation profiling.
    Kloosterhof NK; de Rooi JJ; Kros M; Eilers PH; Sillevis Smitt PA; van den Bent MJ; French PJ
    Genes Chromosomes Cancer; 2013 Jul; 52(7):665-74. PubMed ID: 23629961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequent LOH on 22q12.3 and TIMP-3 inactivation occur in the progression to secondary glioblastomas.
    Nakamura M; Ishida E; Shimada K; Kishi M; Nakase H; Sakaki T; Konishi N
    Lab Invest; 2005 Feb; 85(2):165-75. PubMed ID: 15592495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 60.